244 Transplant immunosuppression drives catastrophic carcinomatosis through IL 22

Catastrophic cutaneous carcinomatosis in the non-organ transplant patient.

BACKGROUND The increased frequency of nonmelanoma skin cancers (NMSCs) in organ transplant recipients has been termed "catastrophic cutaneous carcinomatosis" (CCC). We have treated a cohort of immunocompetent patients with an increased number of NMSCs that meets the definition of CCC whom we have termed "catastrophic cutaneous carcinomatosis-immunocompetent" (CCC-IC). OBJECTIVE We sought to f...

IL 22 ( interleukin 22 )

Complications of Post-Transplant Immunosuppression

Transplantation is one of the revolutionary fields in modern medicine that has saved thou‐ sands of lives. The continuous refinement of surgical techniques and the availability of potent immunosuppressive drugs have made transplantation the most effective treatment option for patients with end stage organ failure. Over 25 000 organ transplants are performed in the USA each year and survival rat...

Gastrointestinal complications of transplant immunosuppression.

At a time when the judicious use of a broad range of immunosuppressive drugs has ensured excellent patient and organ survival rates after kidney transplantation, attention is focusing on strategies to minimize their side effects. Almost all immunosuppressive medications are associated with some form of gastrointestinal (GI) complication (1–6). The majority of these complications fall into one o...

New approaches to transplant immunosuppression.

Although considerable progress has been achieved using immunosuppressive drugs that inhibit lymphocyte activation and T-cell cytokine signal transduction pathways, the widespread tissue distribution of the molecular targets exploited to date, calcineurin, mammalian target of rapamycin, and inosine monophosphate dehydrogenase, engenders a constellation of collateral toxicities. One strategy to d...